Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Globenewswire
- Upsized Offering: Dyne Therapeutics successfully closed an upsized public offering of 21,827,549 shares at $18.44 each, reflecting strong market demand for its therapeutic solutions and expected to provide substantial funding for future R&D initiatives.
- Significant Proceeds: The offering generated approximately $402.5 million in gross proceeds, which will be allocated to advancing clinical programs targeting muscle and central nervous system disorders, particularly myotonic dystrophy and Duchenne muscular dystrophy.
- Strong Underwriter Lineup: Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, enhancing investor confidence in the offering due to their market influence and expertise.
- Effective Registration Statement: The offering was conducted under a shelf registration statement on Form S-3 filed on March 5, 2024, ensuring compliance and transparency, which is likely to bolster investor trust in the company's future growth prospects.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like DYN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on DYN
Wall Street analysts forecast DYN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DYN is 38.40 USD with a low forecast of 17.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.700
Low
17.00
Averages
38.40
High
60.00
Current: 17.700
Low
17.00
Averages
38.40
High
60.00
About DYN
Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Its product candidate, DYNE-101, is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, DYNE-251, is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to exon 51 skipping. Its other product candidates are DYNE-302 and DYNE-401. DYNE-302 addresses the genetic basis of FSHD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
- Clinical Trial Progress: Z-basivarsen demonstrates sustained functional improvement in the ACHIEVE trial, particularly in muscle strength and function, with enrollment for the registrational expansion cohort expected to complete in early Q2 2026, further advancing treatment options.
- Orphan Drug Designation: The MHLW in Japan has granted z-basivarsen orphan drug status for myotonic dystrophy type 1 (DM1), highlighting the urgent need for new therapies and potentially providing up to 10 years of market exclusivity if approved.
- Multiple Designations: Z-basivarsen has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the FDA, along with Orphan Drug designation from the EMA, indicating its development potential and market recognition on a global scale.
- Treatment Need: DM1 affects approximately 40,000 people in the U.S. and 55,000 in the EU, and the development of z-basivarsen aims to address the significant unmet medical need, carrying important social and economic implications.
Continue Reading
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Stock Picks Overview: The second installment of the 2026 Barron’s Roundtable features 30 stock picks from five investment experts, highlighting both well-known companies and lesser-known options.
Familiar Names Included: Among the stock picks are recognizable brands such as Home Depot, Starbucks, and Nike, indicating a mix of established and emerging investment opportunities.
Biodegradable Innovation: The article hints at a British company that has recently acquired a manufacturer of biodegradable sneaker midsoles, showcasing a trend towards sustainable products in the footwear industry.
Investment Insights: The Roundtable serves as a platform for sharing diverse investment strategies and insights, appealing to both seasoned investors and those looking to explore new market trends.
Continue Reading